A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy
A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy
Recruiting · NCT06055439 · Registry updated 2026-01-29Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, colonic disorder, colorectal cancer, colorectal neoplasm, digestive system disorder, digestive system neoplasm, gastric cancer, gastric neoplasm, intestinal disorder, neoplasm, neuroendocrine neoplasm, primitive neuroectodermal tumor, rectal disorder, stomach disorder | Recruiting | Phase 1 / Phase 2 | 2026-01-29 | NCT06055439 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Chimeric Therapeutics | 1 |
4 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Emory University | Atlanta | United States | 262 |
| Sarah Cannon Research Institute | Nashville | United States | 119 |
| University of Chicago | Chicago | United States | 312 |
| University of Pennsylvania | Philadelphia | United States | 507 |